



Review:

Epigenetic and metabolic regulation of breast cancer stem cells^{*}

Hui-xin LIU[§], Xiao-li LI[§], Chen-fang DONG^{†‡}

(Department of Pathology and Pathophysiology, School of Medicine, Zhejiang University, Hangzhou 310058, China)

[†]E-mail: chenfangdong@zju.edu.cn

Received June 25, 2014; Revision accepted Sept. 30, 2014; Crosschecked Dec. 19, 2014

Abstract: Breast cancer has a relatively high mortality rate in women due to recurrence and metastasis. Increasing evidence has identified a rare population of cells with stem cell-like properties in breast cancer. These cells, termed cancer stem cells (CSCs), which have the capacity for self-renewal and differentiation, contribute significantly to tumor progression, recurrence, drug resistance and metastasis. Clarifying the mechanisms regulating breast CSCs has important implications for our understanding of breast cancer progression and therapeutics. A strong connection has been found between breast CSCs and epithelial mesenchymal transition (EMT). In addition, recent studies suggest that the maintenance of the breast CSC phenotype is associated with epigenetic and metabolic regulation. In this review, we focus on recent discoveries about the connection between EMT and CSC, and advances made in understanding the roles and mechanisms of epigenetic and metabolic reprogramming in controlling breast CSC properties.

Key words: Cancer stem cells (CSCs), Epithelial mesenchymal transition (EMT), Epigenetic modification, Metabolic reprogramming, Breast cancer

doi:10.1631/jzus.B1400172

Document code: A

CLC number: R737.9

1 Introduction

Despite medical advances in early detection and treatment, breast cancer still has a relatively high mortality rate in women due to recurrence and metastasis (Jemal *et al.*, 2011). Breast cancer is a heterogeneous disease. This heterogeneity is found not only among different breast tumor subtypes (inter-heterogeneity) but also within the same tumor (intra-heterogeneity) (Almendro and Fuster, 2011). A high degree of diversity between and within tumors, as well as among cancer-bearing individuals, determines the risk of cancer progression and therapeutic resistance (Polyak, 2011). A growing body of evidence has demonstrated that this heterogeneity may originate from the existence of a rare population of

cells with stem cell-like properties in many cancer types, including breast cancer. However, only recently has the cancer stem cell (CSC) hypothesis been supported by biomedical advances. It has been proposed that solid tumors contain a minor proportion of undifferentiated cells with the ability to initiate tumors due to the capacity for self-renewal and differentiation in their progeny. These CSCs, or tumor-initiating cells (TICs), contribute significantly to tumor progression, recurrence, drug resistance and metastasis (Jordan *et al.*, 2006). Clarifying the mechanisms regulating breast CSCs has important implications for our understanding of breast cancer progression and therapeutics. There is increasing evidence that a strong connection exists between breast CSCs and epithelial-mesenchymal transition (EMT) (Mani *et al.*, 2008; Morel *et al.*, 2008; Sarrio *et al.*, 2008; Hennessy *et al.*, 2009). Also, the maintenance of the breast CSC phenotype is related to epigenetic and metabolic mechanisms. In this review, we focus on recent studies on the connection between EMT and CSC, and advances made in our understanding of the roles and mechanisms of epigenetic

[‡] Corresponding author

[§] The two authors contributed equally to this work

^{*} Project supported by the Thousand Young Talents Program of China, the National Natural Science Foundation of China (No. 81472455), and the Fundamental Research Funds for the Central Universities of China

ORCID: Chen-fang DONG, <http://orcid.org/0000-0003-1123-6732>

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2015

and metabolic reprogramming in controlling breast CSC properties.

2 CSC hypothesis and breast CSCs

According to the CSC hypothesis, a tumor is organized as a hierarchy, in which a small subset of CSCs resides at the apex, and terminally differentiated cells lie at the bottom. This hierarchy contributes to the formation of the heterogeneous bulk of the tumor. On the one hand, CSCs can sustain their 'stemness' by symmetrical self-renewal. On the other hand, they can generate lineage-committed progenitor and differentiated cells by asymmetrical division (Wicha *et al.*, 2006).

Al-Hajj *et al.* (2003) first discovered the existence of CSCs in human breast cancer. Cells with an $ESA^+/CD44^+/CD24^{-/low}/lineage^-$ phenotype were isolated from primary breast cancers using fluorescence-activated cell sorting (FACS). This phenotype was more tumorigenic than the $CD44^+/CD24^+$ cell population. Indeed, only 200 cells with this phenotype were able to generate tumors consistently after transplantation into the mammary fat pads of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, whereas as many as 20000 $CD44^+/CD24^+$ cells failed to form tumors. Subsequently, Ginestier *et al.* (2007) identified that as few as 20 cells with a $CD44^{high}/CD24^{low}/ALDH^{high}$ profile were able to form tumors.

Organ-specific stem cells have the capacity for self-renewal and differentiation into the cell types that comprise each organ (Dontu *et al.*, 2003). It is now becoming evident that CSCs can generate different subtypes of breast cancer cells due to limited or aberrant differentiation (Proia *et al.*, 2011; Driessens *et al.*, 2012; Gerhard *et al.*, 2012; Keller *et al.*, 2012). Breast cancer has been divided into six distinct subtypes based on gene expression profiling: the luminal A, luminal B, basal-like, claudin-low, HER2/ERBB2-overexpressing, and normal-breast-like subtypes. The differences in tumor subtypes are hypothesized to reflect differences in the cell of origin (Perou *et al.*, 2000). Basal-B/claudin-low and metaplastic cancers are suggested to originate from primitive basal mammary stem cells, whereas luminal and basal-like tumors may be generated from luminal progenitors.

Indeed, Proia *et al.* (2011) have found that luminal progenitors are the cells of origin for basal-like breast cancers with *BRCA1* and *TP53* mutations. Consistent with this notion, luminal progenitor cells induced by oncogenes can give rise to luminal, basal-like, and possibly HER2 subtypes of breast cancers (Driessens *et al.*, 2012; Gerhard *et al.*, 2012; Keller *et al.*, 2012).

3 EMT and CSCs

EMT is an essential process for morphogenetic events in embryonic development, tissue remodeling, wound healing and metastasis, which enables polarized epithelial cells to acquire a motile mesenchymal phenotype (Polyak and Weinberg, 2009; Thiery *et al.*, 2009). Loss of E-cadherin expression as an important hallmark of EMT has been correlated with increased metastasis in several tumor types, whereas re-expression of E-cadherin inhibits tumor cell invasion and metastasis (Polyak and Weinberg, 2009; Thiery *et al.*, 2009). EMT is required for the first step of the tumor metastasis cascade, as differentiated epithelial cells are not capable of migration and invasion. However, cells with a mesenchymal phenotype cannot develop macrometastasis due to their weak capability for adhesion and proliferation. These cells can be regulated by the reversion of EMT, a process termed mesenchymal to epithelial transition (MET), to colonize new sites and create secondary tumors in distant organs (Nieto, 2011). Thus, EMT is a dynamic and reversible process, which switches between on and off states during the metastasis process.

Breast CSCs can interconvert between a stem cell and a non-stem cell state due to their plasticity. Meyer *et al.* (2009) first reported that non-stem cells ($CD44^+/CD24^+$) were able to generate $CD44^+/CD24^-$ breast CSCs with tumorigenic properties in breast cancer cell lines and *vice versa*. Subsequent studies found that breast CSCs could differentiate into other cell phenotypes, whereas luminal and basal cells could give rise to a similar proportion of breast CSCs (Gupta *et al.*, 2011). Therefore, a shift between a stem cell and a non-stem cell state can occur in specific conditions. This shift is quite similar to the previously described cancer cell plasticity when undergoing EMT or MET. Indeed, growing evidence has demonstrated that EMT can be induced in human

mammary epithelial cells either by treatment with transforming growth factor- β (TGF- β) or by ectopic expression of Snail or Twist, leading to the acquisition of the CD44⁺/CD24^{-low} profile, as well as significantly increased mammosphere formation (Mani et al., 2008; Morel et al., 2008; Sarrio et al., 2008; Hennessy et al., 2009). These results indicate that EMT confers stem cell-like properties on tumor cells, thus making them more tumorigenic and invasive. Interestingly, breast CSCs with a CD44⁺/CD24^{-low} phenotype also exhibit EMT traits, such as reduced expression of E-cadherin and increased expression of vimentin, fibronectin, and EMT inducers (Snail, Slug, and Twist) (Fillmore and Kuperwasser, 2007; Blick et al., 2010). These findings suggest that CSC and EMT may share similar regulatory mechanisms due to their tight interconnections.

4 Epigenetic regulation of breast CSCs

Stem cells are linked to a high degree of plasticity, which is required for cell renewal and differentiation. This plasticity is able to be maintained by reversible epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA modulation (Shah and Allegrucci, 2012). This epigenetic regulation affects gene expression without changing the DNA sequence. Epigenetic modifications also are known to contribute to different stages of tumor development, including initiation, invasion, and metastasis, by controlling CSC plasticity (Allegrucci et al., 2007).

Epigenetic modifications are known to regulate transcriptional plasticity and are important for gene activation and repression during stem/progenitor differentiation. Histone modification is an epigenetic mechanism important for chromatin remodeling. The histone amino-terminals are frequently subject to post-translational modifications, including acetylation, methylation, phosphorylation, and ubiquitination. Among these modifications, acetylation and methylation are considered as potential marks for carrying epigenetic information through cell divisions and conferring unique transcriptional potential (Barski et al., 2007; Campos and Reinberg, 2009). The most well characterized modifications are the methylations of the Lys9 and Lys27 residues of histone H3

(H3K9me2/3 and H3K27me3), which represses gene expression, and H3K4me3 and H3K9 acetylation (H3K9ac), which is associated with gene activation (Shi, 2007). Over-expression of some epigenetic modifiers has been found to induce breast CSC plasticity. For example, the polycomb protein EZH2 has been observed to over-express in high-grade breast cancers, and plays a fundamental role in controlling stem cell self-renewal and differentiation (Bracken et al., 2006; Holm et al., 2012). In addition, high expression of *SUZ12*, a member of the polycomb-repressor complex 2, is known to regulate the transcription of genes essential for maintaining the pluripotency and self-renewal of stem/progenitor cells (Lee et al., 2006; Pasini et al., 2007). DNA methylation has been shown to control gene expression by transcriptional repression and formation of heterochromatin during development, differentiation, and carcinogenesis (McCabe et al., 2009). Epigenetic silencing of genes important for pluripotency and self-renewal by promoter methylation is an essential step in mammary epithelial differentiation. We have mentioned above that CD44⁺/CD24^{-low} cells display stem/progenitor characteristics and undergo lineage-specific differentiation (Al-Hajj et al., 2003). Interestingly, genes related to cellular stemness were hypomethylated and highly expressed in CD44⁺/CD24^{-low} cells compared with the three other differentiated cell types. For example, hypermethylation at the promoters of *SUZ12* gene targets was observed in CD24⁺ cells, but not in CD44⁺/CD24^{-low} cells, indicating that acquired DNA methylation may result in permanent silencing of *SUZ12* targets during mammary epithelial differentiation (Bloushtain-Qimron et al., 2008). The key roles played by miRNAs in the proper maintenance of CSCs have been revealed recently (Mallick et al., 2011). Regulation of miRNA expression might induce the transformation of a lineage-restricted cell into a CSC (Greene et al., 2010). Recent studies have shown the critical role of miRNA in the breast CSC phenotype (Yu et al., 2007; Shimono et al., 2009; Wellner et al., 2009). The silencing of *let-7* contributes to the maintenance of the self-renewal capacity and undifferentiated status in both normal cells and CSCs of the breast (Yu et al., 2007). Another example is *miR-200*, which can inhibit expression of BMI1 (a known self-renewal regulator) by binding to the 3' UTR of BMI1 (Shimono et al.,

2009). In addition, *miR-200* as a stemness-inhibiting miRNA can be repressed by the EMT activator ZEB1 (Wellner *et al.*, 2009). Consistent with this notion, the epigenetic silencing of *miR-200* was observed in breast CSCs (Yu *et al.*, 2007). Together, the flexibility of these epigenetic modifications provides a rapid switch for regulating gene expression during the differentiation process, while retaining cellular plasticity in response to developmental and microenvironmental signals.

The cellular plasticity of CSCs is determined by the EMT program and can be memorized and passed on to daughter cells by epigenetic modifications (Reik, 2007; Campos and Reinberg, 2009; Cedar and Bergman, 2009). Histone lysine methylation plays vital roles in regulating gene expression and chromatin organization. H3K9 methylation is a well-conserved epigenetic mark for heterochromatin formation and transcriptional silencing. Methylation of H3K9 occurs in euchromatin, which requires mono- and dimethylation (H3K9me1 and H3K9me2) mostly by G9a, and in heterochromatin, which involves trimethylation (H3K9me3) mainly by Suv39H1/2 (Grewal and Jia, 2007; Mohn and Schubeler, 2009). The chromatin structure can be regulated by the histone code that can be written by epigenetic enzymes and read by transcription factors or various binding proteins. Snail, as a transcription factor and EMT inducer, contains DNA-binding domain zinc-finger motifs and can bind to a specific DNA motif (E-box sequence) on the promoter of E-cadherin. Using an unbiased protein affinity purification-mass spectrometry coupled technology, we have identified some Snail-binding chromatin modifying enzymes in cells stably expressing human Snail (Lin *et al.*, 2010). We screened several interesting candidates among these enzymes, including G9a and Suv39H1. Our study found that Snail interacted with G9a both *in vitro* and *in vivo* and was required for the enrichment of G9a and the corresponding H3K9me2 at the E-cadherin promoter. DNA methylation is mediated by a family of highly related DNA methyltransferase enzymes (DNMT1, DNMT3a, and DNMT3b) and commonly occurs in the promoter region of genes (Cedar and Bergman, 2009; McCabe *et al.*, 2009). According to our study, Snail also can interact with DNMT1, DNMT3a and DNMT3b, and is responsible for DNA methylation on the promoter of E-cadherin. Our studies also clearly

demonstrated that abolishing Snail-mediated epigenetic regulation led to re-expression of E-cadherin and the reversal of EMT. This suggests that these epigenetic enzymes are able to be recruited to the E-cadherin promoter by Snail to cooperatively cause transcriptional silencing of E-cadherin, thereby becoming involved in the EMT process (Dong *et al.*, 2012). We also investigated another screened Snail-binding protein, Suv39H1. The interaction of Suv39H1 with Snail was critical for the enrichment of H3K9me3 on the E-cadherin promoter in breast cancer cells, and knockdown of Suv39H1 re-activated E-cadherin expression, suggesting a critical role for Suv39H1 in the induction of EMT (Dong *et al.*, 2013a). Furthermore, we identified that knockdown of Snail, G9a and Suv39H1 expression suppressed cell migration and invasion *in vitro* and inhibited metastasis *in vivo* (Dong *et al.*, 2012; 2013a), indicating the critical role of Snail-mediated epigenetic regulation in inducing EMT and sustaining the phenotype of breast CSCs.

5 Metabolic reprogramming in breast CSCs

Somatic cells rely primarily on mitochondrial oxidative phosphorylation (OXPHOS) for their energy production, whereas pluripotent cells mainly use glycolysis (Facucho-Oliveira and St. John, 2009; Armstrong *et al.*, 2010; Prigione *et al.*, 2010). Using an induced pluripotent stem cell (iPSC) as a model in stem cell reprogramming, both glucose uptake and lactate production were higher in iPSCs than in their parental fibroblasts, whereas oxygen consumption was lower. Metaboproteome analysis also revealed that iPSCs had elevated levels of glycolytic enzymes and decreased levels of electron transport chains compared with their parental fibroblasts. Stimulating glycolysis by elevating media glucose levels increased reprogramming efficiency, whereas inhibition of glycolysis reduced reprogramming (Zhu *et al.*, 2010; Folmes *et al.*, 2011). These findings suggest that the process of reprogramming is associated with a major bioenergetic restructuring to facilitate a conversion from somatic mitochondrial oxidation to a glycolysis-dependent pluripotent state. Our recent study has shown that metabolic reprogramming contributes to the acquisition of CSC properties in breast

cancer cells (Dong *et al.*, 2013b). Loss of fructose-1,6-bisphosphatase (FBP1), a rate-limiting enzyme in gluconeogenesis, which catalyzes the splitting of fructose-1,6-bisphosphate (F-1,6-BP) into fructose 6-phosphate and inorganic phosphate, results in a metabolic switch from OXPHOS to aerobic glycolysis in breast cancer cells. Interestingly, loss of FBP1 by Snail-mediated repression is critical for the maintenance of breast CSCs. Indeed, expression of FBP1 in MDA-MB231 and MDA-MB435 cells dramatically reduces the percentage of $ESA^+/CD44^+/CD24^{-/low}$ population and mammosphere formation, whereas knockdown of FBP1 leads to a remarkable increase in the proportion of the population with a CSC phenotype in luminal MCF7 cells. Together, these results indicate that the glycolytic switch due to the loss of FBP1 expression favors the reprogramming of stem cell-like characters in breast cancer.

In the hematopoietic stem cell (HSC) compartment, protection from oxidative stresses, such as reactive oxygen species (ROS) and superoxide, generated mainly by OXPHOS, is critical for the maintenance of self-renewal (Tothova *et al.*, 2007). Similar to HSCs, human and mouse breast CSCs maintain low levels of ROS (Diehn *et al.*, 2009). These intriguing findings indicate that the self-renewal potential of CSCs in different tissues may be sensitive to levels of ROS, and that the glycolytic switch reduces ROS and facilitates the maintenance of the pluripotent state in CSCs. In our study, loss of FBP1 by Snail-mediated repression could decrease mitochondrial ROS by increasing aerobic glycolysis and suppressing oxygen consumption (Dong *et al.*, 2013b). ROS can mediate the regulation of the Wnt pathway. The Wnt pathway, which modulates the expression of specific target genes through β -catenin, is a critical regulator of stem cells and CSCs (Clevers, 2006). β -Catenin exists in two transcriptional complexes (Bowerman, 2005): (1) β -catenin promotes cell proliferation and stem cell-like properties through its binding with TCF transcription factors; and (2) β -catenin interacts with FOXO to favor the exit from the cell cycle and entry into quiescence. A low level of ROS activates Wnt signaling and favors the interaction of β -catenin with TCF instead of FOXO. Essers *et al.* (2005) identified that the reduced ROS mediated by loss of FBP1 shifted the interaction of β -catenin towards TCF4 instead of FOXO3a, leading

to the activation of the Wnt signaling pathway. Snail-mediated metabolic regulation of EMT may be another important reason for the acquisition of CSC properties in breast cancer. Our study found that ectopic FBP1 expression inhibited morphological changes indicative of EMT, indicating the importance of FBP1 for this event (Dong *et al.*, 2013b). These findings are in line with the notion that expression of FBP1 suppresses CSC phenotypes and tumorigenicity. Clinically, loss of FBP1 is linked to poor patient survival. Clearly, metabolic reprogramming by loss of FBP1 not only changes the metabolic phenotype, but also contributes significantly to the increased CSC phenotypes that are associated with the clinically aggressive behavior of breast cancer.

6 Concluding remarks

Here, we have reviewed the interconnections between CSCs and EMT, and summarized the key roles and mechanisms of epigenetic and metabolic reprogramming in EMT and breast CSCs. The epigenetic and metabolic program in EMT and CSCs is a complicated transcriptional and regulatory network, which reversibly controls the plasticity of EMT and breast CSCs (Fig. 1).




Fig. 1 Schematic representation of the crosstalk among epigenetic regulation, metabolic reprogramming, EMT, and CSCs

Breast CSCs contribute to tumor growth and metastasis and are resistant to conventional therapies, such as chemotherapy and radiotherapy. Theoretically, removing CSCs will stop new tumor growth. Thus, careful assessment of breast CACs and their regulatory networks is needed to devise targeted therapeutic strategies. The plasticity of EMT provides an intriguing mechanism for understanding tumor progression and metastasis, as it allows cancer cells to reversibly transition between epithelial and mesenchymal phenotypes, as well as between stemness and differentiation. Blocking EMT may decrease the invasive ability of cancer cells and increase their sensitivity to traditional therapies. However, the metastatic cells participate in the establishment and stabilization of distant metastases by reversing EMT and regaining epithelial properties. In this regard, simply blocking EMT may not efficiently prevent the cancer metastasis. Thus, more information about the regulatory network of EMT needs to be explored before targeting EMT can become a successful method in managing breast cancer. Epigenetic changes may represent a vulnerable point in the self-defense mechanisms of cancer cells, as epigenetic silencing of tumor-suppressor genes can be reactivated with the right inhibitors. In fact, 5-aza-2'-deoxycytidine, a hypomethylating agent, has been used as a drug for the treatment of acute myeloid leukemia. Thus, identifying inhibitors that act specifically on DNMTs, G9a and/or Suv39H1 may hold a great promise for breast cancer therapy. Interfering with stem cell self-renewal not only is the strategy of choice, but also presents a great challenge because many regulatory mechanisms are shared by CSCs and their normal counterparts. Based on the metabolic difference between breast CSCs and normal cells, elucidating how metabolic reprogramming is involved in maintaining breast CSC properties will provide new strategies for breast cancer treatment. Further clarification of the mechanisms regulating breast CSCs has important implications not only for our understanding of breast cancer, but also for the development of cancer therapeutics.

Acknowledgements

We apologize to colleagues whose work was not cited here due to our oversight.

Compliance with ethics guidelines

Hui-xin LIU, Xiao-li LI, and Chen-fang DONG declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

- Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., *et al.*, 2003. Prospective identification of tumorigenic breast cancer cells. *PNAS*, **100**(7):3983-3988. [doi:10.1073/pnas.0530291100]
- Allegrucci, C., Wu, Y.Z., Thurston, A., *et al.*, 2007. Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome. *Hum. Mol. Genet.*, **16**(10):1253-1268. [doi:10.1093/hmg/ddm074]
- Almendro, V., Fuster, G., 2011. Heterogeneity of breast cancer: etiology and clinical relevance. *Clin. Transl. Oncol.*, **13**(11):767-773. [doi:10.1007/s12094-011-0731-9]
- Armstrong, L., Tilgner, K., Saretzki, G., *et al.*, 2010. Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. *Stem Cells*, **28**(4):661-673. [doi:10.1002/stem.307]
- Barski, A., Cuddapah, S., Cui, K., *et al.*, 2007. High-resolution profiling of histone methylations in the human genome. *Cell*, **129**(4):823-837. [doi:10.1016/j.cell.2007.05.009]
- Blick, T., Hugo, H., Widodo, E., *et al.*, 2010. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44^{hi}/CD24^{lo/-} stem cell phenotype in human breast cancer. *J. Mammary Gland Biol. Neoplasia*, **15**(2):235-252. [doi:10.1007/s10911-010-9175-z]
- Bloushtain-Qimron, N., Yao, J., Snyder, E.L., *et al.*, 2008. Cell type-specific DNA methylation patterns in the human breast. *PNAS*, **105**(37):14076-14081. [doi:10.1073/pnas.0805206105]
- Bowerman, B., 2005. Cell biology. Oxidative stress and cancer: a β -catenin convergence. *Science*, **308**(5725):1119-1120. [doi:10.1126/science.1113356]
- Bracken, A.P., Dietrich, N., Pasini, D., *et al.*, 2006. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev.*, **20**(9):1123-1136. [doi:10.1101/gad.381706]
- Campos, E.I., Reinberg, D., 2009. Histones: annotating chromatin. *Annu. Rev. Genet.*, **43**(1):559-599. [doi:10.1146/annurev.genet.032608.103928]
- Cedar, H., Bergman, Y., 2009. Linking DNA methylation and histone modification: patterns and paradigms. *Nat. Rev. Genet.*, **10**(5):295-304. [doi:10.1038/nrg2540]
- Clevers, H., 2006. Wnt/ β -catenin signaling in development and disease. *Cell*, **127**(3):469-480. [doi:10.1016/j.cell.2006.10.018]
- Diehn, M., Cho, R.W., Lobo, N.A., *et al.*, 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature*, **458**(7239):780-783. [doi:10.1038/nature07733]
- Dong, C., Wu, Y., Yao, J., *et al.*, 2012. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. *J. Clin. Invest.*, **122**(4):1469-1486. [doi:10.1172/JCI57349]

- Dong, C., Wu, Y., Yao, J., et al., 2013a. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. *Oncogene*, **32**(11):1351-1362. [doi:10.1038/onc.2012.169]
- Dong, C., Yuan, T., Wu, Y., et al., 2013b. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. *Cancer Cell*, **23**(3):316-331. [doi:10.1016/j.ccr.2013.01.022]
- Dontu, G., Abdallah, W.M., Foley, J.M., et al., 2003. *In vitro* propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes Dev.*, **17**(10):1253-1270. [doi:10.1101/gad.1061803]
- Driessens, G., Beck, B., Caauwe, A., et al., 2012. Defining the mode of tumour growth by clonal analysis. *Nature*, **488**(7412):527-530. [doi:10.1038/nature11344]
- Essers, M.A., de Vries-Smits, L.M., Barker, N., et al., 2005. Functional interaction between β -catenin and FOXO in oxidative stress signaling. *Science*, **308**(5725):1181-1184. [doi:10.1126/science.1109083]
- Facucho-Oliveira, J.M., St. John, J.C., 2009. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. *Stem Cell Rev. Rep.*, **5**(2):140-158. [doi:10.1007/s12015-009-9058-0]
- Fillmore, C., Kuperwasser, C., 2007. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man. *Breast Cancer Res.*, **9**(3):303.
- Folmes, C.D., Nelson, T.J., Martinez-Fernandez, A., et al., 2011. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. *Cell Metab.*, **14**(2):264-271. [doi:10.1016/j.cmet.2011.06.011]
- Gerhard, R., Ricardo, S., Albergaria, A., et al., 2012. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. *Breast*, **21**(3):354-360. [doi:10.1016/j.breast.2012.03.001]
- Ginestier, C., Hur, M.H., Charafe-Jauffret, E., et al., 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, **1**(5):555-567. [doi:10.1016/j.stem.2007.08.014]
- Greene, S.B., Herschkowitz, J.I., Rosen, J.M., 2010. Small players with big roles: microRNAs as targets to inhibit breast cancer progression. *Curr. Drug Targets*, **11**(9):1059-1073. [doi:10.2174/138945010792006762]
- Grewal, S.I., Jia, S., 2007. Heterochromatin revisited. *Nat. Rev. Genet.*, **8**(1):35-46. [doi:10.1038/nrg2008]
- Gupta, P.B., Fillmore, C.M., Jiang, G., et al., 2011. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. *Cell*, **146**(4):633-644. [doi:10.1016/j.cell.2011.07.026]
- Hennessy, B.T., Gonzalez-Angulo, A.M., Stenke-Hale, K., et al., 2009. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res.*, **69**(10):4116-4124. [doi:10.1158/0008-5472.CAN-08-3441]
- Holm, K., Grabau, D., Lovgren, K., et al., 2012. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. *Mol. Oncol.*, **6**(5):494-506. [doi:10.1016/j.molonc.2012.06.002]
- Jemal, A., Bray, F., Center, M.M., et al., 2011. Global cancer statistics. *CA Cancer J. Clin.*, **61**(2):69-90. [doi:10.3322/caac.20107]
- Jordan, C.T., Guzman, M.L., Noble, M., 2006. Cancer stem cells. *N. Engl. J. Med.*, **355**(12):1253-1261. [doi:10.1056/NEJMra061808]
- Keller, P.J., Arendt, L.M., Skibinski, A., et al., 2012. Defining the cellular precursors to human breast cancer. *PNAS*, **109**(8):2772-2777. [doi:10.1073/pnas.1017626108]
- Lee, T.I., Jenner, R.G., Boyer, L.A., et al., 2006. Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell*, **125**(2):301-313. [doi:10.1016/j.cell.2006.02.043]
- Lin, Y., Wu, Y., Li, J., et al., 2010. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. *EMBO J.*, **29**(11):1803-1816. [doi:10.1038/emboj.2010.63]
- Mallick, B., Chakrabarti, J., Ghosh, Z., 2011. MicroRNA reins in embryonic and cancer stem cells. *RNA Biol.*, **8**(3):415-426. [doi:10.4161/rna.8.3.14497]
- Mani, S.A., Guo, W., Liao, M.J., et al., 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*, **133**(4):704-715. [doi:10.1016/j.cell.2008.03.027]
- McCabe, M.T., Brandes, J.C., Vertino, P.M., 2009. Cancer DNA methylation: molecular mechanisms and clinical implications. *Clin. Cancer Res.*, **15**(12):3927-3937. [doi:10.1158/1078-0432.CCR-08-2784]
- Meyer, M.J., Fleming, J.M., Ali, M.A., et al., 2009. Dynamic regulation of CD24 and the invasive, CD44^{pos}CD24^{neg} phenotype in breast cancer cell lines. *Breast Cancer Res.*, **11**(6):R82. [doi:10.1186/bcr2449]
- Mohn, F., Schubeler, D., 2009. Genetics and epigenetics: stability and plasticity during cellular differentiation. *Trends Genet.*, **25**(3):129-136. [doi:10.1016/j.tig.2008.12.005]
- Morel, A.P., Lievre, M., Thomas, C., et al., 2008. Generation of breast cancer stem cells through epithelial-mesenchymal transition. *PLoS ONE*, **3**(8):e2888. [doi:10.1371/journal.pone.0002888]
- Nieto, M.A., 2011. The ins and outs of the epithelial to mesenchymal transition in health and disease. *Annu. Rev. Cell Dev. Biol.*, **27**(1):347-376. [doi:10.1146/annurev-cellbio-092910-154036]
- Pasini, D., Bracken, A.P., Hansen, J.B., et al., 2007. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. *Mol. Cell. Biol.*, **27**(10):3769-3779. [doi:10.1128/MCB.01432-06]
- Perou, C.M., Sorlie, T., Eisen, M.B., et al., 2000. Molecular portraits of human breast tumours. *Nature*, **406**(6797):747-752. [doi:10.1038/35021093]

- Polyak, K., 2011. Heterogeneity in breast cancer. *J. Clin. Invest.*, **121**(10):3786-3788. [doi:10.1172/JCI60534]
- Polyak, K., Weinberg, R.A., 2009. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat. Rev. Cancer*, **9**(4):265-273. [doi:10.1038/nrc2620]
- Prigione, A., Fauler, B., Lurz, R., et al., 2010. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. *Stem Cells*, **28**(4):721-733. [doi:10.1002/stem.404]
- Proia, T.A., Keller, P.J., Gupta, P.B., et al., 2011. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. *Cell Stem Cell*, **8**(2):149-163. [doi:10.1016/j.stem.2010.12.007]
- Reik, W., 2007. Stability and flexibility of epigenetic gene regulation in mammalian development. *Nature*, **447**(7143):425-432. [doi:10.1038/nature05918]
- Sarrio, D., Rodriguez-Pinilla, S.M., Hardisson, D., et al., 2008. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res.*, **68**(4):989-997. [doi:10.1158/0008-5472.CAN-07-2017]
- Shah, M., Allegrucci, C., 2012. Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. *Breast Cancer (Dove Med. Press)*, **4**:155-166. [doi:10.2147/BCTT.S26434]
- Shi, Y., 2007. Histone lysine demethylases: emerging roles in development, physiology and disease. *Nat. Rev. Genet.*, **8**(11):829-833. [doi:10.1038/nrg2218]
- Shimono, Y., Zabala, M., Cho, R.W., et al., 2009. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. *Cell*, **138**(3):592-603. [doi:10.1016/j.cell.2009.07.011]
- Thiery, J.P., Acloque, H., Huang, R.Y., et al., 2009. Epithelial-mesenchymal transitions in development and disease. *Cell*, **139**(5):871-890. [doi:10.1016/j.cell.2009.11.007]
- Tothova, Z., Kollipara, R., Huntly, B.J., et al., 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell*, **128**(2):325-339. [doi:10.1016/j.cell.2007.01.003]
- Wellner, U., Schubert, J., Burk, U.C., et al., 2009. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nat. Cell Biol.*, **11**(12):1487-1495. [doi:10.1038/ncb1998]
- Wicha, M.S., Liu, S., Dontu, G., 2006. Cancer stem cells: an old idea—a paradigm shift. *Cancer Res.*, **66**(4):1883-1890; discussion 1895-1896. [doi:10.1158/0008-5472.CAN-05-3153]
- Yu, F., Yao, H., Zhu, P., et al., 2007. *let-7* regulates self renewal and tumorigenicity of breast cancer cells. *Cell*, **131**(6):1109-1123. [doi:10.1016/j.cell.2007.10.054]
- Zhu, S., Li, W., Zhou, H., et al., 2010. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. *Cell Stem Cell*, **7**(6):651-655. [doi:10.1016/j.stem.2010.11.015]

中文概要

题目：表观遗传修饰和代谢重编程对乳腺癌干细胞的调控

概要：乳腺癌已居我国女性恶性肿瘤死亡率首位。近来研究表明，乳腺肿瘤组织内有少量具有自我更新和分化潜能的肿瘤干细胞，这些肿瘤干细胞在乳腺癌发生、发展、转移及复发过程中起关键作用。深入研究乳腺癌干细胞的调控机制对乳腺癌的预防和治疗具有十分重要意义。本文综合近期的研究成果，概括了表观遗传修饰和代谢重编程对上皮间质转化及乳腺癌干细胞的调控机制，且系统地分析与总结了表观遗传修饰、代谢重编程、上皮间质转化和乳腺癌干细胞之间的相互关系。

关键词：肿瘤干细胞；上皮间质转化；表观遗传修饰；代谢重编程；乳腺癌